DEF: Firefly Neuroscience Seeks Shareholder Approval for Major Equity Expansion

Firefly Neuroscience, Inc. will hold its Annual Meeting on October 27, 2025, seeking stockholder approval for director elections, auditor ratification, and significant increases in its equity incentive plan and total authorized shares.

Summary

• Stockholders will vote on five proposals at the Annual Meeting on October 27, 2025, including the election of two Class II directors, ratification of Marcum Canada LLP as the independent auditor for fiscal year 2025, and approval of an amendment to the 2024 Long-Term Incentive Plan.
• The proposed amendment to the 2024 Long-Term Incentive Plan seeks to increase the maximum number of shares available for grant by 317,820 shares, raising the limit from 833,333 to 1,151,153 shares of common stock.
• The Plan Share Limit will also automatically increase annually from January 1, 2026, to January 1, 2035, to the lower of 4% of outstanding common stock or a Board-determined number.
• A significant proposal involves authorizing the Board to amend the Certificate of Incorporation to increase the total number of authorized shares from 101,000,000 to up to an aggregate of 5,001,000,000, comprising up to 5,000,000,000 common shares and a fixed 1,000,000 preferred shares.
• The Board unanimously recommends a vote FOR all five proposals, including the election of directors, auditor ratification, and the two equity-related proposals.
• As of the Record Date, September 4, 2025, there were 13,448,848 shares of common stock issued and outstanding and entitled to vote.

Sentiment

Score: 3

Explanation: While the company is taking steps to address governance and secure future operational flexibility, the substantial net losses, poor historical Total Shareholder Return, and the 'going concern' warning from its former auditor indicate significant underlying financial challenges. The proposed massive increase in authorized shares, while enabling future capital raises, also presents a high risk of significant dilution for existing shareholders.

Positives

• The Board has established robust corporate governance structures, including independent Audit, Compensation, and Nominating and Corporate Governance Committees.
• A Code of Business Conduct and Ethics, Insider Trading Policy, and Clawback Policy have been adopted to ensure compliance and accountability.
• The proposed amendments to the Long-Term Incentive Plan and the increase in authorized shares aim to provide flexibility for attracting and retaining key talent and facilitating future capital raises and strategic transactions.

Negatives

• Reported a significant net loss of $(10,460,000) for the fiscal year ended December 31, 2024, an increase from $(2,603,000) in 2023.
• The cumulative Total Shareholder Return (TSR) for an initial $100 investment was $3.67 as of December 31, 2024, indicating substantial value erosion over the past three years (down from $39.97 in 2022).
• The previous independent auditor, Turner Stone & Company LLP, included an explanatory paragraph in its reports for 2023 and 2022, stating there was substantial doubt about the company's ability to continue as a going concern.

Risks

• The former independent auditor's reports for the years ended December 31, 2023, and 2022, contained an explanatory paragraph indicating substantial doubt about the company's ability to continue as a going concern.
• Future issuance of additional shares of common stock, if the Board implements the authorized share increase, could have a dilutive effect on the earnings per share, book value per share, voting power, and ownership interest of existing stockholders, potentially depressing the market price of the common stock.
• Failure to approve Proposal 4 (increase in authorized shares) may result in an insufficient number of unreserved shares for future issuance, potentially delaying capital raises or other strategic transactions.

Future Outlook

The company aims to enhance its ability to attract and retain key employees, contractors, and non-employee directors through an expanded equity incentive plan. The significant increase in authorized shares is intended to provide greater flexibility for future capital raising transactions, potential acquisitions, investment opportunities, strategic agreements, and other corporate purposes, as market conditions permit.

Management Comments

• The Board unanimously recommends a vote FOR the election of two Class II directors, the ratification of Marcum Canada LLP as the independent registered public accounting firm, the approval of an amendment to the 2024 Long-Term Incentive Plan, the approval of the Board's discretion to implement amendments to the Certificate of Incorporation to increase authorized shares, and the approval of the adjournment of the Annual Meeting if necessary.

Industry Context

The company operates in the neuroscience sector, which often requires substantial capital for research, development, and commercialization. The reliance on equity-based compensation and the need for flexible capital raising mechanisms, including increasing authorized shares, are common strategies for growth-stage companies in this industry, particularly those with significant operating losses and a focus on long-term value creation.

Management Changes

Corporate Governance

Related Party Transactions

• Prior to the merger, G. James Benoit, Jr. (former WaveDancer Chairman and CEO) purchased 50,000 shares of WaveDancer common stock for $600,000 in August 2022 and 35,000 shares for $175,000 in September 2023.
• James C. DiPaula (former WaveDancer director) purchased 20,834 shares for $250,000 in August 2022.
• William C. Pickle (former WaveDancer director) purchased 4,167 shares for $50,000 in August 2022.
• Greg Lipschitz, through Bower Four Corp., is entitled to receive aggregate consideration of $950,000 in common stock over three years for services under a strategic agreement dated August 12, 2024.
• Greg Lipschitz's employment agreement (March 27, 2025) entitles him to restricted stock units representing 3.0% of outstanding common stock (fully diluted) and an annual base salary of $300,000.
• David DeCaprio's employment agreement (April 18, 2025) entitles him to restricted stock units representing 2.0% of outstanding common stock (fully diluted) and an annual base salary of $250,000.

Stakeholder Impact

• Shareholders face potential significant dilution if the Board exercises its discretion to issue a large number of the newly authorized shares, which could negatively impact per-share metrics and stock price.
• Employees and management benefit from the expanded equity incentive plan, which is designed to attract, retain, and motivate key personnel through stock options and restricted stock units.
• The company's ability to raise capital and pursue strategic initiatives (e.g., acquisitions) is enhanced by the increased authorized share count, potentially benefiting long-term growth prospects if successfully executed.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on October 27, 2025.
• If approved, the Board may implement amendments to the Certificate of Incorporation to increase authorized shares at its discretion.
• The 2024 Long-Term Incentive Plan will see automatic annual increases in its share limit from January 1, 2026, until January 1, 2035.
• Voting results will be published in a Current Report on Form 8-K within four business days of the Annual Meeting.

Key Dates

Recommendation

The company faces significant financial challenges, as evidenced by substantial net losses and poor total shareholder return, coupled with a prior 'going concern' warning. While the proposed increase in authorized shares and equity incentive plan provides necessary flexibility for future capital raises and talent retention, it also introduces a high risk of significant dilution for existing shareholders. The current proposals are primarily procedural for future operational flexibility rather than indicators of immediate financial improvement. A seasoned investor would likely hold, awaiting clearer signs of operational turnaround and effective use of the expanded capital capacity, while closely monitoring the dilutive impact of future share issuances.

Keywords

Firefly Neuroscience, Proxy Statement, Annual Meeting, Equity Incentive Plan, Authorized Shares, Corporate Governance, Executive Compensation, Dilution, Nasdaq, SEC Filing